Zealand Pharma A/S
ZEALN/A
NASDAQHealthcare🇺🇸North America
Drugs in Pipeline
9
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Aug 13, 2026
10wMarket Overview
Stock performance and key metrics
ZEAL News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
GlucaGen
Hypoglycemia
Glepaglutide
Short Bowel Syndrome
dasiglucagon
Hypoglycemia
Insulin Lispro
Diabetes Mellitus, Type 1
ZP4207
Hypoglycemia
ZP4207(dasiglucagon) glucagon analogue
Diabetes Mellitus Type 1
ZP1848
Short Bowel Syndrome
Petrelintide
Obesity
danegaptide
Focus of Study is STEMI
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GlucaGen | Phase 3 | Hypoglycemia | - | - |
Glepaglutide | Phase 3 | Short Bowel Syndrome | - | - |
dasiglucagon | Phase 3 | Hypoglycemia | - | - |
Insulin Lispro | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
ZP4207 | Phase 2 | Hypoglycemia | - | - |
ZP4207(dasiglucagon) glucagon analogue | Phase 2 | Diabetes Mellitus Type 1 | - | - |
ZP1848 | Phase 2 | Short Bowel Syndrome | - | - |
Petrelintide | Phase 2 | Obesity | - | - |
danegaptide | Phase 2 | Focus of Study is STEMI | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply